PDF(Pubmed)
Abstract：
Heart failure (HF) is a syndrome characterized by the heart failing to pump blood to the body at a rate proportional to its needs. HF is a public health burden globally and one of the leading causes of hospitalizations in adults. While many classes of drugs have been introduced for the treatment of HF, not every drug may be well-tolerated by patients. In this narrative review, we describe a few of the newer classes of medications proposed to be efficacious in treating acute and chronic HF. We focus on vericiguat, omecamtiv mecarbil, ularitide, and serelaxin, and thoroughly examine their efficacy and safety profiles while summarizing the clinical trials of the drugs. There is a need for more long-term studies comparing the efficacy of these medications to the conventional ones.
摘要：
心力衰竭（HF）是一种综合征，其特征是心脏无法以与其需求成正比的速度将血液泵入身体。HF是全球范围内的公共卫生负担，也是成年人住院的主要原因之一。虽然已经引入了许多类别的药物用于治疗HF，并非每种药物都能被患者良好耐受。在这篇叙述性评论中，我们描述了一些新类型的药物建议是有效的治疗急性和慢性HF。我们专注于vericiguat，omecamtivmecarbil,ularitide,还有serelaxin,并在总结药物临床试验的同时彻底检查其疗效和安全性。需要更多的长期研究来比较这些药物与常规药物的疗效。
